Water in pharma and healthcare

Significance of the Topic

The purity of laboratory water is a fundamental parameter in pharmaceutical and healthcare analytics. Contaminated water can compromise assay accuracy, lead to false results, and create safety risks in processes such as therapeutic drug monitoring, active pharmaceutical ingredient quantification, forensic toxicology, and hospital diagnostics. Ensuring ultrapurity reduces background interference, enhances sensitivity, and supports regulatory compliance.

Study Objectives and Overview

This interactive exploration examines four critical application areas impacted by water quality:

• Therapeutic Drug Monitoring: accuracy of drug concentration measurements in patient plasma.
• API Measurement: assessment of active pharmaceutical ingredient content and dissolution behavior.
• Forensic Toxicology: detection of drugs in biological matrices including blood, urine, and hair.
• Hospital Environment: role of ultrapure water in diagnostic assays, pathogen identification, and precision medicine.

Methodology and Instrumentation

• Assay Techniques: immunoassays, HPLC, LC-MS/MS for multi-analyte quantification.
• Sampling Protocols: timed blood collection at steady-state for TDM; dissolution testing for API release profiling.
• Analytical Matrices: evaluation of blood, urine, and hair samples with and without ultrapure water background.
• Instrumentation: high-performance liquid chromatographs, mass spectrometers, dissolution testers, automated water purification systems (e.g., ELGA LabWater).

Key Results and Discussion

• Contaminated water introduced significant background noise, peak suppression, and analytical variability across all assays.
• Use of ultrapure water markedly improved signal-to-noise ratios, reduced ionization suppression in LC-MS/MS, and provided consistent dissolution profiles in API testing.
• Forensic analyses demonstrated enhanced limits of detection in hair and biological fluid assays when using ultrapure water.
• Hospital diagnostic workflows benefited from reduced assay interference, leading to more reliable biomarker and pathogen identification.

Benefits and Practical Applications

Use of ultrapure water in pharmaceutical and healthcare laboratories:

• Enhances the accuracy and reliability of therapeutic drug monitoring, minimizing patient risk.
• Supports robust quality control for both branded and generic APIs through precise dissolution and content analysis.
• Enables sensitive forensic toxicology testing for clinical, legal, and anti-doping applications.
• Improves hospital diagnostic outcomes by ensuring valid results in bioanalysis and pathogen screening.

Instrumentation

The studies employed:

• High-Performance Liquid Chromatography (HPLC)
• Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)
• Immunoassay platforms
• Dissolution testing apparatus
• Automated water purification systems delivering ultrapure water

Future Trends and Opportunities

• Integration of real-time water quality monitoring in analytical workflows.
• Advances in membrane and electrodeionization technologies for point-of-use purification.
• Development of miniaturized, portable analytical platforms coupled with on-demand ultrapure water generation.
• Application of machine learning to predict and prevent contamination events in laboratory systems.

Conclusion

Maintaining ultrapure water standards is essential to safeguard analytical integrity across pharmaceutical and healthcare applications. By minimizing contamination, laboratories can ensure precise, reproducible data, comply with regulatory requirements, and ultimately protect patient safety.

References

• Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med. 2013;3(9):a015487.
• Therapeutic drug monitoring guidelines. ARUP Consult. Accessed May 2020.
• McMaster MC. HPLC and column maintenance. In: LC/MS: A Practical User’s Guide. Wiley; 2005:33.
• European Pharmacopoeia 7th ed. EDQM, Strasbourg; 2011.
• Zhang X et al. Mechanistic oral absorption modeling: FDA perspective. CPT Pharmacometrics Syst Pharmacol. 2017;6(8):492–495.
• Anand O et al. Dissolution testing for generic drugs: FDA perspective. AAPS J. 2011;13(3):328–335.
• FIP/AAPS guidelines for dissolution testing. Accessed May 2020.
• EMA. Guideline on the quality of water for pharmaceutical use. 2020.
• Hadland SE, Levy S. Urine and other drug tests. Child Adolesc Psychiatr Clin N Am. 2016;25(3):549–565.
• WADA anti-doping testing figures report. Accessed May 2020.
• EWDT Society European guidelines for hair testing. 2015.
• Boumba VA et al. Hair as indicator of drug exposure. Int J Toxicol. 2006;25(3):143–163.
• Herath HM et al. Ionization suppression in HPLC/MS. Rapid Commun Mass Spectrom. 2010;24(11):1502–1506.
• Waritani T et al. ELISA protocol improvement. MethodsX. 2017;4:153–165.
• Dancer SJ. Role of environment in infection control. Clin Microbiol Rev. 2014;27(4):665–690.
• Eisfeld AJ et al. Influenza A virus isolation. Nat Protoc. 2014;9(11):2663–2681.
• McLaurin MD et al. Cardiac biomarkers in dialysis. Clin Chem. 1997;43(6 Pt 1):976–982.
• Water in instrument processing. Infection Control Today. Accessed May 2020.
• Rashid MA et al. Medication adherence in coronary disease. Ann Fam Med. 2014;12(3):224–232.